Pharmacotherapy for co-morbidities in chronic heart failure: a focus on hematinic deficiencies, diabetes mellitus and hyperkalemia

Haye H. van der Wal, Niels Grote Beverborg, Dirk J. van Veldhuisen, Adriaan A. Voors, Peter van der Meer*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

2 Citations (Scopus)

Abstract

INTRODUCTION: Chronic heart failure (HF) is frequently accompanied by one or more co-morbidities. The presence of co-morbidities in chronic HF is strongly correlated to HF severity and impaired outcome.

AREAS COVERED: This review will address several co-morbidities with high prevalence and/or high impact in patients with chronic HF, including diabetes, anemia, hematinic deficiencies, and hyperkalemia. The background and subsequent pharmacotherapeutic options of these co-morbidities will be discussed. For this review, a MEDLINE search was performed.

EXPERT OPINION: Heart failure is increasingly considered a multimorbid syndrome, including metabolic derangements and chronic inflammation. Persistent metabolic derangements and low-grade inflammation might lead to progression of HF and the development of co-morbidities. Although several co-morbidity-specific drugs became available in the past decade, most of these therapies are studied in relatively small cohorts using surrogate end-points. Therefore, larger studies are needed to address whether treating these co-morbidities will improve patient outcome in chronic HF.

Original languageEnglish
Pages (from-to)1527-1538
Number of pages12
JournalEXPERT OPINION ON PHARMACOTHERAPY
Volume17
Issue number11
DOIs
Publication statusPublished - 2016

Keywords

  • Heart failure
  • comorbidities
  • anemia
  • iron deficiency
  • diabetes mellitus
  • hyperkalemia
  • hematinics
  • vitamin B12
  • folic acid
  • CHRONIC KIDNEY-DISEASE
  • SODIUM ZIRCONIUM CYCLOSILICATE
  • PRESERVED EJECTION FRACTION
  • INTRAVENOUS FERRIC CARBOXYMALTOSE
  • SYSTEMIC IRON HOMEOSTASIS
  • RANDOMIZED CLINICAL-TRIAL
  • PLACEBO-CONTROLLED TRIAL
  • QUALITY-OF-LIFE
  • DOUBLE-BLIND
  • DARBEPOETIN-ALPHA

Cite this